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1.  Introduction 
Human germline genetic modification is theoretically possible: the technologies of animal 
transgenesis (pronuclear microinjection, sperm-mediated gene transfer, nuclear transfer, etc) could in 
principle be applied to humans. The purpose of this paper is to consider the potential for applying the 
available genetic modification (GM) technologies to the goal of achieving human germline gene 
therapy. 
If germline gene therapy does become a technically viable proposition, one crucial question must 
be asked: Why do it? There is in effect a ‘golden rule’ applying to disorders potentially amenable to 
germline gene therapy: in any disorder with enough molecular knowledge available to allow the 
prospect of germline gene therapy, that same knowledge should also be sufficient to allow detection of 
the disease-causing sequences via embryo pre-screening. Given the low transfer efficiencies and safety 
risks available at present (i.e. extrapolating from animal transgenesis), candidate disorders would have 
to be severe and unavoidable by pre-screening. However, it is conceptually possible that gene transfer 
technologies improve to the point at which it becomes easier and safer to perform germline gene 
therapy than to carry out embryo pre-screening. In this futuristic scenario of expanded genetic 
knowledge coupled with effective gene transfer technology, germline GM might become the preferred 
therapeutic route. 
The possibility of human germline genetic modification raises several important and vexing 
bioethical issues, including questions of responsibility towards future generations, difficulties of 
distinction between gene therapy and genetic enhancement, and the spectre of eugenics [1, 2, 3]. Thus, 
human germline genetic modification is far more ethically contentious than somatic gene therapy. 
However, such bioethical matters are beyond the scope of the present discussion. Instead, this paper 
focuses solely upon scientific issues related to human germline gene therapy. 
2. Criteria for Assessing Applicability to Human Germline Gene Therapy 
An ideal gene transfer system in the context of human germline gene therapy would have the 
following features: (a) the ability to deliver transgenes in a highly efficient manner; (b) non-prohibitive 
cost and expertise requirements; (c) minimal risk of causing insertional DNA damage; (d) low rate of 
mosaicism; (e) high DNA carrying capacity; (f) the ability to permit adequate and controlled transgene 
expression; and (g) the ability to target transgenes to precise genomic loci. 
Unfortunately, no single system amongst the presently available systems is able to provide all of 
features (a-g) above. Indeed, some gene transfer systems are so thoroughly unsuited to human germline 
gene therapy that they are not considered here. Of the systems that offer some positive features, in every 
case major drawbacks exist. In each case, particular scientific advances are required before the methods 
would be suitable for use in human germline gene therapy. In this respect, methods that require a 
relatively small degree of scientific research should be seen as more plausible than methods requiring 
many years of progress towards distant (possibly unobtainable) goals. 
3. Gene Transfer to Human Embryos 
Most transgenic animals have been produced via the introduction of transgenes into embryos, and 
the associated technology and underpinning science is accordingly well developed. Thus, the human 
embryo is a potential candidate for human germline gene therapy. 
Unless dramatic improvements in the technologies are forthcoming, certain transfection methods 
are not at present a realistic proposition for gene transfer into human zygotes. Such methods include 
liposome-mediated gene transfer, electroporation, naked DNA uptake and many viral vectors. The 
problem is one of low transfection frequencies, coupled with fact that zygotes must be harvested (as 
opposed to grown in vitro). This leaves pronuclear microinjection and retroviral transfer as the only 
contenders presently available that might be adapted for use with embryos in human germline gene 
therapy.   
Pronuclear Microinjection 
Jon Gordon in 1980 demonstrated that exogenous DNA could be introduced into the germline 
simply by the physical injection of a solution of cloned DNA into zygote pronulei [4]. Subsequently, 
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pronuclear microinjection has become the most widely used method of germline gene transfer, despite 
the fact that it remains an intrinsically costly and laborious approach. The technique is most established 
with mice, however gene transfer via pronuclear microinjection has also been carried out with a wide 
range of other mammals including rats, rabbits, and farmyard animals. Accordingly, it is to be expected 
that the human zygote should in principle be similarly amenable to gene tranfer via pronuclear 
microinjection. The microinjection technique is intrinsically simple, although it requires expensive 
equipment and high levels of skill [5]. A fine glass needle is loaded with DNA solution. Under the 
microscope, the needle is guided through the cytoplasm towards one of the zygote’s pronuclei. A 
nanolitre quantity of DNA solution is injected, bringing typically two hundred DNA molecules into the 
pronucleus. 
Pronuclear microinjection would be an obvious choice of transgene delivery method for human 
embryos. The technique is well established in animals, and is likely to be directly applicable to the 
human zygote [6, 7, 8]. Zygotes from various mammalian species have particular characteristics that 
necessitate amendments to the basic (murine) technique. For example, bovine and porcine zygotes are 
optically opaque, due to the presence of lipid granules in the cytoplasm; this necessitates centrifugation 
to displace the obscuring cytoplasmic material such that the pronuclei become visible. Similarly, the 
pronuclei in ovine zygotes are very difficult to visualise, due to sharing a very similar refractive index 
with the cytoplasm; this necessitates the use of top-quality optics, such as differentiation interference 
contrast (DIC) microscopy, instead of standard phase contrast microscopy. Thus, empirical adjustments 
enable pronuclear microinjection to be employed with zygotes from essentially any mammal. It would 
be surprising and unfortunate if the human zygote proved to be an exception to this rule. Indeed, 
visualisation of the pronuclei in human fertilised eggs is not problematic. 
Although pronuclear microinjection would probably be usable with human zygotes, the major 
inherent problems of the method render it less than ideal for human germline gene therapy. A major 
problem is the relatively low rate of transgene integration: in mice, the overall efficiency of transgenesis 
(taking into account embryo loss in vitro and in vivo) is typically ca. 2% [9, 10, 11]. This level of 
efficiency is perfectly practicable for animal transgenesis, but it would be problematic for humans. 
Moreover, murine pronuclear microinjection transgene uptake values are several times higher than 
those achieved with other (non-rodent) species. Accordingly, even with hormonal induction of 
superovulation, the numbers of zygotes available per woman would be a strongly limiting factor in the 
potential use of pronuclear microinjection for human germline gene therapy. 
Embryo pre-screening (preimplantation genetic screening) might be one possible way around the 
problem of low transgene uptake efficiency. Using established techniques, one or two blastomeres 
could be taken from 8 cell stage embryos and analysed by PCR for the presence of transgene DNA. 
However, such pre-screening would not be 100% reliable, due to mosaicism within the early embryo. 
Following microinjection and successful integration of the transgene sequences, the transgene would be 
expected to be present in only 50% of the resulting blastomeres. Assuming that in humans, as with 
mice, 3 blastomeres are recruited to form the entire inner cell mass (ICM) [12, 13], then 1 in 8 of the 
resulting individuals would contain no transgene sequences, another 1 in 8 would contain transgene 
sequences in 100% of their cells, and the remaining 6 from 8 individuals would be mosaics, consisting 
of 1/3rd or 2/3rd transgene-containing cells. Accordingly, pre-screening would have a failure rate of 
more than 50%. The only feasible way that pre-screening might work at an acceptable level of 
efficiency would be to screen blastocyst-stage embryos. However, blastocyst biopsy techniques are in 
their infancy, and it remains to be seen whether such techniques could be applied to ICM cells (as 
opposed to trophoblast cells). 
Extrapolating from murine data, it would typically require ca. 50 zygotes to produce one 
genetically modified individual. Assuming 8 eggs per superovulation cycle, it would take 
approximately 6 months per woman to obtain 50 eggs. Pronuclear microinjection involving such a 
period of time, if coupled with effective blastocyst pre-screening to select for the small number of 
transgene–containing embryos, might be a feasible means of performing human germline gene therapy. 
However, reported pronuclear microinjection efficiency values are significantly lower for most 
mammals other than mice. If human pronuclear microinjection turned out to have a similar efficiency as 
that obtained with sheep or pigs, then the time taken per genetically modified individual would be ca. 5-
fold longer – i.e. more than 2.5 years. And if the rate of transgenesis turned out to be similar to that 
obtained with cattle, the time would extend beyond 8 years. The efficiency of transgene uptake through 
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pronuclear microinjection is simply not known for humans, nor can it be known a priori. Thus, a 
circular problem exists: only if the efficiency turned out to be fortuitously high (i.e. similar to murine 
rates) would there be any point in attempting the technique with humans – but the necessary data on 
efficiency could only come from actual attempts with humans. 
Another problem associated with pronuclear microinjection concerns transgene expression. Only 
around 60% of pronuclear microinjection-derived mice show transgene expression. Furthermore, in the 
animals showing expression, there are frequently problems of low-level expression or inappropriate 
expression (e.g. non-tissue-specific, non-temporal). Accordingly, pronuclear microinjection as a means 
to human germline gene therapy requires improvements in transgene expression. It is the non-targeted 
nature of transgene integration associated with pronuclear microinjection that is the root cause of 
expression problems. Some improvements may come from advances in transgene design, such as the 
use of matrix attachment regions (MARs) or locus control regions (LCRs): placed on either side of a 
gene within a transgene construct, these ‘insulator’ sequences appear to allow the gene to occupy a 
separate chromosomal domain and thus avoid position-related expression problems [14]. However, the 
best solution would be to target transgenes to precise genomic loci, and at present this is not possible 
with pronuclear microinjection. Given the fact that even the best designs of targeting transgene undergo 
random integration more frequently than targeted integration, the only foreseeable way to achieve high 
efficiency gene targeting with pronuclear microinjection would be to stimulate homologous 
recombination (HR) by co-injecting appropriate recombinase enzymes with the transgene. However, 
elucidation of such enzymes is at an early stage, and it remains to be seem whether this approach could 
ever provide the quantum leap improvements in targeting efficiency that would be required in the case 
of human germline gene therapy. 
Random integration also raises the concern that an endogenous gene will be damaged by transgene 
insertion. The degree of risk for any one insertion event must approximate to the proportion of coding 
sequences (plus controlling elements) within the human genome, a figure of no more than 2%. Thus, 
endogenous gene damage may be expected to occur in around 1 in every 50 human zygotes integrating 
transgene DNA. In embryos sustaining such damage, there are several possible outcomes: (a) where a 
developmentally crucial gene is damaged, the result is likely to be embryo death, and the subsequent 
non-appearance of a genetically modified individual; (b) where one allele of an important gene is 
affected, haplosufficiency may permit the development of a normal or near-normal genetically modified 
individual; (c) where a non-essential gene is affected (such as an allele for hair colour, or a repeated 
gene), the resulting genetically modified individual may contain a phenotypic change that has no health 
implications; or (d) where an important gene is affected, debility is likely to occur in the resulting 
genetically modified individual. Outcomes (a-c), while not desirable, would not necessarily be highly 
problematic, and the occurrence of these outcomes means that the undesirable outcome (d) would occur 
at a frequency significantly lower than 1 in 50 genetically modified individuals. Nevertheless, such 
magnitude of risk implies that pronuclear microinjection in its present stage of development is not 
acceptable as a means to human germline gene therapy. 
Retroviral Transfer 
The genome of retroviruses can be manipulated to carry exogenous DNA. Retroviral vectors 
(RVVs) are one of the most frequently employed forms of gene delivery in somatic gene therapy [15, 
16, 17]. Additionally, RVVs are able to deliver genes to the germline, as established in animal 
transgenesis [18, 19, 20]. Zygotes may be incubated in media containing high concentrations of the 
resultant retroviral vector. Alternatively, retroviral vector-producing cell monolayers may be used, upon 
which zygotes are co-cultivated. In either case, up to ca. 90% of (surviving) embryos will be infected. 
Following zygote transfer into pseudopregnant females, the infected embryos should give rise to 
transgenic offspring. Molecular genetic analysis of transgenics produced in this way usually show 
integration of a single proviral copy into a given chromosomal site. Rearrangements of the host genome 
are normally restricted to short direct repeats at the site of integration. In many embryos the germline 
cells contain viral integrants: thus, transmission of the transgene to the next generation will often occur. 
Methods have also been developed to allow infection into postimplantation embryos. In this context, 
virus uptake is effective for many somatic cell lines, however germline cells are infected at low 
frequency, due to a high level of mosaicism [15, 16]. 
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Retroviral transfer remains an alternative to pronuclear microinjection in the context of human 
germline gene therapy. Traditional RVVs would be of minimal potential use, due to the high levels of 
mosaicism associated with these vectors. However, the new generation of lentiviral vectors would avoid 
such problems [21, 22, 23]. These vectors have the additional advantage of high gene transfer rates (70-
80% of animals born are transgenic). Accordingly, lentiviral vectors represent plausible candidates for 
human germline gene therapy. However, the small insert capacity (9-10 kb) would preclude the transfer 
of many human genes. Additionally, control possibilities are less with RVV delivered transgenes 
compared with transgenes delivered by microinjection. 
The safety problems associated with RVVs (insertional oncogenesis, viral reactivation) would also 
be a major concern [24, 25, 26]. In principle, judicious genetic alteration of the lentivirus genome 
would ensure that the resultant vector would have a very high level of safety. However, given the 
critical context of human germline gene therapy, one would have to question whether our basic 
scientific understanding of retroviruses is sufficiently advanced to empower rational vector design. 
Somatic gene therapy provides a salutary lesson here. Human trials involving several hundred patients 
have been carried out for over a decade using RVVs. Despite the theoretical risks referred to above, a 
lack of reports of serious adverse affects has resulted in a growing acceptance of the practical safety of 
RVVs. However, it has been recently reported that two patients (both young children) being treated for 
X-linked severe combined immunodeficiency disease (SCID-X) using RVV-based vectors have 
developed leukaemia. In both patients, RVV had integrated into a gene (LMO2) known to cause 
leukaemia if activated inappropriately. It is not known why the same endogenous gene had been 
targeted by the RVV concerned. The full cause of leukaemia in these patients is still under 
investigation, however the fact that both patients share the same integration site, coupled with the fact 
that the patients were both from the same (10-patient) trial, strongly implicates the particular RVVs 
employed in this trial [27, 28, 29]. Indeed, clinical trials involving this particular RVV-based therapy 
have been halted pending further investigations and pre-clinical trials [30]. It is to be hoped that 
enhanced RVV design will prevent any recurrence of iatrogenic leukaemia or similar serious adverse 
affects in somatic gene therapy. However, the occurrence of such adverse RVV effects lends weight to 
the argument that more basic virology is needed before any potential human germline gene therapy 
RVV could be deemed sufficiently safe. At the very least, extensive in vitro (cell culture) and in vivo 
(mammalian transgenesis) experimentation would be required in order to establish the safety of any 
proposed RVV (lentiviral-based or otherwise) for human germline gene therapy. 
Microinjection of Retroviral Vector 
A combination of microinjection with retroviral vectors has proved successful with bovines [31] 
and primates [32]. In the primate case, microinjection was used to deliver a retroviral vector into the 
perivitelline space of 224 mature rhesus oocytes. (The oocytes were subsequently fertilized by 
intracytoplasmic sperm injection.) The retroviral vector particles had an envelope type known to 
recognise and bind to the membrane of all cell types. The retroviral vector was microinjected at a 
developmental stage at which the oocyte nuclear membrane was absent, thus permitting nuclear entry. 
From 20 embryo transfers, three animals were born, one of which was transgenic. Additionally, a 
miscarried pair of twins was transgenic. Although this ‘combined’ method of gene transfer is laborious, 
it is the only approach that has permitted the generation of transgenic primates thus far. 
Given the success with primates of microinjection of RVV into oocytes, this approach is likely to 
be effective for human germline gene therapy. The drawbacks would be similar to those associated with 
(a) microinjection (i.e. embryo loss) and (b) RVVs (i.e. transgene size limitations, problems with 
control of expression, safety risks). The process would also be laborious, but it would be expected to 
avoid the problems of mosaicism associated with most RVVs. Additionally, this form of gene transfer 
might require fewer eggs than required for pronuclear microinjection. The reported overall rate of 
transgenesis with rhesus monkeys was 1.3%; although this compares unfavourably with murine 
efficiencies (up to ca. 6% transgenic), it is significantly better than the rates achieved for animals such 
as sheep, cows and pigs. Moreover, this ‘combined’ technique is in its infancy, and its efficiency may 
well improve with use.  
4. Sperm-mediated Gene Transfer 
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The scientific literature contains over forty reports of the successful in vitro uptake of exogene 
constructs (transgenes) by animal sperm cells [33, 34]. A majority of these reports provide evidence of 
post-fertilisation transfer and maintenance of transgenes. Several of the studies report the subsequent 
generation of viable progeny animals, the cells of which contain transgene DNA sequences. While a 
minority of studies have used ‘augmentation’ techniques (electroporation or liposomes) to ‘force’ sperm 
to capture exogenes, the standard methodology is very straightforward: prior to in vitro fertilisation 
(IVF) or artificial insemination (AI), ‘washed’ sperm cells are simply incubated in a DNA-containing 
solution. As a potential tool for genetically manipulating animals, sperm-mediated gene transfer 
(SMGT) has the advantages of simplicity and cost-effectiveness, in contrast with more established 
methods of transgenesis such as pronuclear micrinjection. 
However, despite the above successes and regardless of its potential utility, SMGT has not yet 
become established as a reliable form of genetic modification. Concerted attempts to utilise SMGT have 
often produced negative results. The most notable example of such a failure is to be found in the 
collated results of several independent research groups: of 890 mice analysed, not a single animal 
contained transgene DNA [35]. 
Indeed, some biologists have expressed scepticism of the fundamental basis for SMGT [36, 37]. 
Such scepticism is posited on the assumption that major evolutionary chaos would result if sperm cells 
were able to act as exogene vectors. Given that the reproductive tracts contain ‘free’ DNA molecules 
(originating from natural cell death and breakage), it seems reasonable to expect sperm cells to be 
highly resistant to the risk of picking up such molecules [38]. 
Nevertheless, there exists a fairly well established body of empirical data showing that sperm cells 
are able, at least under particular experimental circumstances, to interact with and carry exogenes [39, 
40]. Furthermore, isolated reports of the successful use of SMGT for genetic modification continue to 
be published. A notable recent example is the generation of several transgenic pigs following the 
artificial insemination of sows with sperm cells preincubated with transgene DNA [41, 42]. 
There are two possible ways to make sense of the above experimental and theoretical 
considerations. The first possible explanation is that SMGT is fundamentally unattainable. If so, the 
empirical evidence in support of SMGT must be faulty. For example, perhaps sperm can associate with 
exogenous DNA but cannot convey the DNA into the oocyte; and transgene sequences may have been 
erroneously identified in tissue samples, perhaps due to DNA contamination affecting sensitive 
detection methods such as PCR. This scenario is certainly not impossible: scientific research contains 
several examples of theory being misled by mistaken data. Indeed, early reports of SMGT were 
compared with the (then contemporary) claims of “cold fusion” in physics [36]. By contrast, the second 
possible explanation is that SMGT is viable, and that the claims of experimental success were not made 
in error. In this case, the explanation for the successful results must be that certain favourable factors 
applied in the fortuitous cases in which transgenes were taken up and transferred by sperm. 
Accordingly, several researchers have made efforts to elucidate such hidden parameters. 
Underpinning such research into hidden factors has been the notion of the existence of ‘inhibitory’ 
factors (IFs) associated with sperm cells. These IFs are envisaged to prevent exogenous DNA uptake so 
as to protect the genetic integrity of the conceptus.  The corollary of this notion is that successful 
instances of sperm cells taking up exogenous DNA may be attributed to the fortuitous removal or 
inhibition of IF(s) [43].  
Seminal fluid reportedly contains an inhibitory factor (IF-1) that appears to actively block the 
binding of exogenous DNA to sperm and to the above-mentioned proteins [44].  Additionally, three 
classes of proteins identified in sperm cells have been claimed to exhibit DNA-binding properties [44, 
45]. There is also some evidence that the binding of transgene DNA can trigger the activation of 
endogenous nucleases in sperm cells, which cleave both transgene and sperm chromosomal DNA [46, 
47, 48]. The possible existence of IF(s) or other mechanisms against foreign DNA may explain the 
varied and often negative results obtained from attempts to use sperm to act as transgene vectors. 
A superficial binding of exogenous DNA to sperm cells would be very unlikely to result in 
successful transgenesis, given the rigours of fertilisation. Conceptually, therefore, it is necessary to 
envisage the exogenous DNA being actively taken up by the sperm cell. Ultrastructural 
autoradiographic studies have indicated that exogenous DNA becomes concentrated within the posterior 
part of the nuclear area of the head, the inference being that binding of DNA by the sperm is followed 
by internalisation [49, 50]. 
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One very interesting possibility is the combination of naked DNA autouptake with microinjection, 
a process that has been termed ‘transgenICSI’. In this recent approach, sperm exposed to naked 
transgene molecules are microinjected into oocytes. Success has been reported with mice, with 
approximately 20% of founder animals integrating and expressing the transgene [51, 52]. Transgene 
uptake and expression following transgenICSI has also been reported in rhesus monkey embryos [53, 
54] and porcine embryos [55, 56], although transgenic offspring did not result. 
The success of transgenICSI provides support for the notion that sperm are indeed able to act as 
transgene vectors. However, some caution is required in making such a conclusion. Firstly, the 
experiments conducted need to be repeated and built upon before it can be said with certainty that the 
effect is a real one. Secondly, it could be the case that the trangene molecules bound only weakly to the 
sperm cells, such that only direct delivery (by ICSI) permitted the DNA to remain in place. If so, then 
this would not support the notion that SMGT can work when used with IVF or AI, because weakly 
bound or superficially located DNA might be stripped away and lost from the incoming pronucleus 
during fertilisation. If it were correct that ICSI is an indispensable part of the process, then SMGT 
would appear to have little advantage over pronuclear microinjection in terms of inherent technical 
difficulties and expense. However, the efficiency of the process does appear to be somewhat better than 
that of pronuclear microinjection. The available experimental data on standard human ICSI (i.e. not 
involving genetic modification) indicate that: (a) the majority (ca. 75%) of eggs are successfully 
fertilised; and (b) lysis following ICSI occurs at a relatively low rate (ca. 10%) [57, 58, 59]. For 
transgenICSI, the reported rates of success (i.e. transgenics per transfer) vary, but a figure of around ca. 
35% is fairly typical [51, 52, 53, 54, 55, 56]. 
Whereas it would be somewhat surprising if sperm cells have the inherent ability to easily capture 
and transfer naked transgene molecules such that the DNA remains in place during fertilisation, it 
remains conceptually possible to use transfection techniques to ‘force’ sperm cells to capture (and thus 
transfer) exogenous DNA. Success has been claimed in this regard using electroporation and liposome-
mediated gene transfer. Since 1990, several reports claiming successful transgene uptake and/or transfer 
following electroporation of sperm cells have been published, and there have been a number of reports 
of sperm cells taking up liposome-encapsulated DNA [34]. More research is clearly needed to 
determine whether and to what extent transfection techniques such as liposome-mediated gene transfer 
or electroporation may be able to augment SMGT. Nevertheless, given that these gene transfer 
techniques have been shown to work with a wide range of somatic cell types, in vitro and in vivo, there 
is no reason to presume that sperm cells are inherently unable to be transfected using such methods. 
An alternative possibility could be to introduce the transgene into testicular (sperm) stem cells in 
vivo. This would in principle remove the need to collect, manipulate or transfer eggs, thus providing a 
major streamlining of germline GM. Preliminary results have been reported in mice, where transgene 
constructs were directly injected into the testis. For example, 60-70% of sperm were reported to carry 
the transgene following injection of naked DNA into the vas deferens [60], with a follow-up report 
claiming detection of the transgene in the cells of 7.5% of offspring animals produced following 
fertilisation with the transgene-bearing sperm [61]. Similar results were reported by Sato et al, using 
liposome-encapsulated transgene molecules injected close to the epididymis [62, 63, 64]. 
In vitro gene delivery into ex vivo spermatogonial stem cells of both adult and immature animals 
has recently been reported [65]. Nagano et al obtained stable transgene integration and expression in up 
to 20% of murine spermatogonial stem cells following retroviral transgene delivery [66]. Genetically 
modified stem cells were transferred into the testes of infertile recipient mice, leading to transgeneity in 
ca. 4.5% of the resultant progeny, plus successful transmission to subsequent generations. Similar 
results were obtained by Orwig et al in rats [67]. Although this form of transgenesis is at an early stage 
of development, preliminary work with spermatogonial stem cells in other mammals such as pigs and 
goats suggests that the approach is likely to be widely applicable [68, 69]. If human ex vivo 
spermatogonial stem cells are similarly able to pick up and transmit transgenes, an exciting potential 
route to germline gene therapy might emerge. 
If SMGT does indeed work as reported, or if it can be made to work, then this would have very 
profound implications for human germline gene therapy. Gene transfer into embryos (using pronuclear 
microinjection or RVVs) is inherently very costly and technically demanding, due in large part to the 
need to remove embryos from the female, to manipulate the embryos and finally to return the embryos 
to the reproductive tract. By contrast, SMGT coupled with AI would permit germline GM with 
Int. J. Med. Sci. 2004 1(2): 76-91 
 
83 
minimum levels of expense and expertise, as would SMGT coupled with testicular injections. Thus, 
SMGT would in principle permit the widespread use of human germline gene therapy: relatively poor 
countries would be able to use the technique, and highly centralised facilities would not be required. Of 
course, such easily available human germline gene therapy would raise serious ethical concerns. 
However, even if SMGT were to prove effective as a means to gene transfer, it would be 
fundamentally limited in the context of human germline gene therapy due to its unsuitability as a means 
of gene targeting. This limitation is of course shared with the embryo-based gene transfer methods 
considered above. However, there are at least some glimmers of hope for future gene targeting 
possibilities in the case of embryo-based approaches: some (albeit very limited) success has been 
achieved with targeting RVVs [70], and the low natural rate of HR in zygotes might conceivably be 
increased if appropriate recombinase enzymes were to be discovered and co-injected [71]. By contrast, 
there have been no reports of gene targeting using SMGT, and it is difficult to envisage even in outline 
how this might ever be achieved. 
5. Episomal Vectors 
Various extrachromosomal plasmid vectors (episomes) have been used as transgenes [72, 73]. 
Such vectors have been employed to produce transgenic animals, via a variety of routes including 
pronuclear microinjection and SMGT [74, 75, 76]. In the context of human germline gene therapy, such 
vectors offer the potential advantage of eliminating the threat to genome integrity associated with 
uncontrolled genomic integration. However, in transgenic animals, episomal plasmid vectors tend to 
behave in an unstable fashion [76, 77]. During development, plasmid copy numbers fluctuate and 
plasmids are lost from some cells. Plasmid inheritance to subsequent generations of animals is similarly 
problematic. Moreover, worrying health problems (such as tumour formation) have been associated 
with some episomal vectors [78]. Of course, the behaviour of an episome must relate in large part to its 
genetic constitution, and therefore stability problems and safety limitations may in principle be 
surmounted by improved plasmid design. However, until such improvements are realised, episomal 
plasmid vectors could not be considered for human germline gene therapy. 
Autonomous artificial ‘mini-chromosomes’, (mammalian artificial chromosomes, MACs) have 
been constructed and successfully introduced into mammalian cells [79, 80]. MACs comprise 
centromeres, telomeres and replication origins, and are maintained autonomously within the host cell. 
Structural genes, promoters and enhancers (etc) can be included in MACs. Preliminary research 
indicates that MACs can be used, via pronuclear microinjection, to create transgenic animals in which 
the MACs are maintained autonomously [81]. In the context of human germline gene therapy, these 
specialised constructs would be expected to give a number of benefits compared with integrated 
transgenes, including higher and more controllable expression. More speculatively, MACs may be able 
to function as genetic ‘platforms’ for the safe subsequent receipt of incoming transgenes. Although this 
technology is in its infancy, MACs would appear to hold significant future potential for human 
germline gene therapy [81, 82, 83, 84, 85]. 
6. Totipotent Cells 
At present, gene targeting requires the use of in vitro selection in order to enrich for rare targeted 
cells amongst a majority of random integration cells. In vitro selection cannot be conducted on embryos 
or sperm cells. Consequently, gene targeting in the context of human germline gene therapy would 
require gene transfer to be carried out with some form of dividing cells in vitro. 
ESCs 
Inner cell mass (ICM) cells from the mouse blastocyst can be propagated in vitro as embryonic 
stem (ES) cells [86, 87]. In contrast to other cultured cell lines, ESCs retain their normal karyotype even 
after many months in culture, during which time they remain totipotent. Furthermore, ESCs are capable 
of colonising the embryo. These unique properties allow ESCs to form chimeras when injected into 
blastocysts or aggregated with morulae. The resultant embryos can be transferred to the uterus of a 
pseudopregnant female mouse for gestation. In cases where an ESC has successfully contributed to the 
embryo, the resultant offspring will be chimeric (up to ca. 50% of animals). The ESC contribution to a 
mouse can high (up to ca. 80% of the cells), and will often include the germline cells. However, it 
should be noted that, with some transgenes, the production of chimeras can be problematic or even 
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unattainable, especially when germline transmission is required to breed pure lines of heterozygous or 
homozygous animals [86, 87, 88, 89].  
It is during the in vitro culture stage that ESCs may be transgenically manipulated [90, 91]. Many 
gene delivery systems are effective with ESCs, including viral vectors, liposomes, and electroporation. 
The great advantage of ESCs is that they can be subjected to a range of selective agents in vitro, which 
allows the selection of particular transgenic modifications. This ability makes ESCs extremely useful 
for gene targeting experiments and applications [92], [93]. 
However, the use of ESCs is limited due to the fact that, to date, the mouse is the only animal from 
which ESC lines have been unequivocally established. It would be surprising if this limitation 
represents a fundamental biological barrier. However, further empirical work is needed before 
totipotent ESC lines become available for other species. Indeed, efforts to isolate non-murine ESCs 
have been ongoing for nearly two decades but to date no germline-competent ESCs have been isolated 
in other vertebrates [94, 95]. 
In 1998, Thomson et al isolated ESCs from human blastocysts [96]. 
Subsequently many other researchers have also isolated human ESCs [97, 98, 99, 100], and a new 
field in biology has resulted. Furthermore, gene targeting has been achieved in human ESCs [101]. 
However, totipotency has not been demonstrated in any human ESC line. Unfortunately, this may prove 
to be a rather intractable situation: proof of totipotency could only (given current technology) come 
from the establishment of a chimeric human being. It is manifest that the necessary experiments 
required to pursue this goal would be ethically unacceptable. Thus, the ESC route presently remains 
firmly closed against human germline gene therapy.  
Nuclear Transfer 
The successful transfer of ‘reprogrammed’ sheep donor nuclei has recently been achieved [102, 
103, 104]. Unfertilised, metaphase-stage enucleated (‘universal recipient’) eggs received the transferred 
nuclei. Donor nuclei originated from somatic cells that had been forced into a form of cell cycle stasis 
(by incubating the cells in a minimal nutrient medium), such that DNA replication and gene expression 
were halted (or virtually so). Nuclear transfer was conducted by depositing a donor cell under the zona 
pellucida of a universal recipient egg, and fusing the two cells by electrical stimulation. This process 
resulted (in some cases) in successful embryo development, the donor nuclei having been 
‘reprogrammed’ into totipotency. Offspring were produced following the transfer of such 
‘reconstructed’ embryos to recipient ewes. Subsequent molecular genetic testing showed that the lambs’ 
DNA had originated from the donor cells. In some of the experiments, the donor nuclei were obtained 
from embryo-derived cultured cell lines. Following these groundbreaking experiments, successful 
cloning from cultured cells of various mammals including cattle, goats and pigs has been reported [105, 
106]. Interestingly, a human ESC line has recently been derived from cloned human blastocysts 
produced by NT [107], pointing to a possible new field of application for NT technology. 
The prospects for germline GM via NT are very significant: transgenes can be introduced to 
somatic donor cells in vitro, permitting germline genetic modifications. This has been achieved in 
animals [103]. Several gene delivery systems are applicable to NT, including liposomes and 
electroporation. Moreover, because selection can be applied to cultured donor cells, NT can be used to 
achieve germline gene-targeting. Gene targeted transgenic animals have been created in this way [108, 
109]. Thus, NT is potentially able to provide the same range of transgenic manipulations presently 
available in mice (via the ESC route) to all mammal species. Accordingly, it seems probable that the 
technique could in principle be readily applied to humans as a means to achieving germline 
modifications. 
However, in comparison with ESC transgenesis, NT has thus far proved to be relatively inefficient: 
only a small proportion of reconstructed embryos survive to become live animals. For example, 
McCreath et al produced live targeted sheep at an efficiency of less than 4% [109], and Lia et al 
produced live targeted pigs at an efficiency of less than 2% [110]. Such low efficiencies, presuming 
reconstructed human embryos to behave similarly, represent a potential problem for human NT-based 
germline gene therapy. Although embryo pre-selection could be used to ensure that only transgene-
containing embryos were allowed to gestate, the problem would remain that a large number of valuable 
donor eggs would be required for each GM attempt. 
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The health status of NT-derived animals is also proving to be problematic [111, 112]. 
Developmental abnormalities are very common, and frequently result in death (foetal or postnatal) or 
debility. For example, of fourteen live-born lambs, seven died within 30 hours of birth, and four died 
within twelve weeks [109]. Similarly, out of seven piglets, two piglets died shortly after birth, and one 
died at 17 days; only one appeared to be entirely free of developmental abnormalities [110]. 
Transgenesis and gene targeting are not of themselves implicated: the health problems are associated 
with NT per se. During the in vitro (cell culture) stage, the pattern of chromosomal imprinting may 
change; there are indications that inappropriate expression of imprinted genes following such epigenetic 
alteration may be mainly responsible for the poor health of NT-derived animals [113, 114, 115]. 
Research into epigenetic reprogramming in NT embryos is in progress, and it is to be hoped that 
developmental abnormalities arising from NT will eventually be eliminated or reduced in frequency. 
Meanwhile, it is anticipated that NT-related health problems, to the extent that the basis for such is 
epigenetic, are unlikely to affect the offspring of surviving first-generation animals. However, until 
such time as the first-generation health problems are solved, NT appears to be too dangerous to consider 
for human germline gene therapy. This is unfortunate, because without NT (or human ESCs) the in 
vitro selection required for germline gene targeting cannot be conducted. Thus, germline GM in humans 
would be restricted to ‘add-in’ alterations; gene knockout and gene repair germline alterations in 
humans are not a practical proposition with the technology available at present. 
Non-selective gene targeting 
In embryonic stem cells and in certain somatic cells in vitro, unusually high levels of gene 
targeting have been reported. Isogenic transgenes, derived from the same (syngenic) laboratory animal 
strain as the target animal, contain homology blocks that are genetically identical (or virtually identical) 
to the target homology regions. Riele et al [116] reported a 20-fold improvement in targeting efficiency 
when an isogenic transgene was used to target the retinoblastoma susceptibly gene (Rb) in murine 
ESCs, yielding a remarkably favourable ratio of random to targeted integration (approximately 1:4). 
Similar results were obtained from a systematic study by Vandeursen and Wieringa [117], in which the 
creatine kinase M gene (CKM) in ESCs was targeted. 
More recently, adeno-associated virus (AAV) vectors have been used to gene target somatic cells 
at high frequencies. Hirata et al used AAV vectors to introduce transgenes into the hypoxanthine 
phosphoribosyl transferase (HPRT) and Type I collagen (COL1A1) loci in normal human fibroblasts 
[118]. The transgenes were targeted at high frequencies, such that the majority of transgene-containing 
cells had undergone gene targeting with an appropriately designed vector. AAV targeting frequencies 
have been further improved by selective creation of double-strand DNA breaks in the target site [119, 
120]. Most recently, adult human mesenchymal stem cells (MSCs) have also been targeted with high 
efficiency using AVV vectors [121]. 
The foregoing reports suggest that in ESCs and in certain somatic cells the efficiency of gene 
targeting can be sufficient to bypass the need for selection. Selection-based gene targeting places limits 
on transgene design, due to the need to engineer the requisite selective elements into the transgene. 
Therefore, the ability to conduct gene targeting in somatic cells without the need for selection would be 
a welcome addition to the armamentarium of gene transfer technologies that may in future permit 
human germline gene therapy.  
7. Conclusions 
It is probable that the human germline could be readily manipulated using current transgenic 
techniques. To achieve this, pronuclear microinjection would probably be effective, as would retroviral 
transfer, particularly using lentivirus-based vectors. A combination of microinjection and RVVs would 
probably be most effective – indeed such a combination has recently given rise to the first transgenic 
primates. SMGT may be effective also, at least in some forms of the approach, such as transgenICSI. 
However, AI-based SMGT is not yet an established method of transgenesis, therefore the prospects for 
this potentially very important form of gene transfer are less certain. Totipotent human ESCs have not 
been established for humans, thus ESC-based gene transfer remains – despite its effectiveness in mice – 
unavailable for human germline gene therapy. The lack of human ESCs leaves NT-based gene transfer 
as the only method that might be able to permit gene targeting in human germline gene therapy. NT 
could probably be readily applied to humans; however, the high level of health problems observed in 
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first generation NT-derived animals render the approach in its present form unfeasible for human 
germline gene therapy. Table 1 summarises the key features of the major candidate methods that might 
serve to achieve human germline gene therapy. 
If human gene transfer technology is limited to adding-in gene functions via non-targeted 
transgene integration, and if the process needs be performed on individual embryos isolated from the 
reproductive tract, it is likely that human germline gene therapy will remain insufficiently safe, 
excessively inefficient and of inadequate clinical value to permit its use. The widespread availability 
and applicability of safe and effective human germline gene therapy would require the development of 
gene transfer methods that would (a) permit gene targeting while (b) avoiding the need for ex vivo 
embryo isolation and manipulation. Unfortunately, at present these two requirements are mutually 
exclusive. Laborious manipulations involving large numbers of embryos would in principle best be 
avoided by the use of SMGT, either in vivo or ex vivo. However, high-efficiency gene targeting is not 
available at present without the use of in vitro selection. Thus, the widespread use of human germline 
gene therapy does not appear likely to flow from incremental improvements in current GM methods. 
Rather, widespread human germline gene therapy would appear to be a future possibility that must 
await substantial scientific advancement. Naturally, it is impossible to predict when such improvements 
might be forthcoming. 
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Tables 
TABLE 1. Gene Transfer Methods 
 
Pronuclear 
micro-
injection 
Retroviral 
transfer 
Micro-
injection 
of 
Retroviral 
Vector 
Sperm-
mediated 
Gene 
transfer 
Embryonic 
Stem Cells 
Nuclear 
Transfer 
Gene 
targeting 
possible? 
No (rate is 
too low) 
No (not yet 
established
) 
No (not yet 
established
) 
No (not 
possible) Yes Yes 
Overall 
efficiency Up to ca. 6% 
Up to ca. 
80% 
Presently 
1.3% 
Up to ca. 
80% 
Up to ca. 
25% 
Up to ca. 
4% 
Cost / 
Expertise 
requirements 
Very high High Very high 
Low (except 
for 
transgenICSI 
and 
SMGT+IVF) 
Very high Very high 
Genetic 
damage risk < 2% 
High: 
varies 
depending 
upon 
vector 
High: 
expected to 
vary 
depending 
upon 
vector 
< 2% 
Low if gene 
targeting 
involved; 
some 
epigenetic 
problems 
Low if gene 
targeting 
involved, 
but serious 
epigenetic 
problems 
Mosaicism 
(F0)? Yes: ca. 65% 
Not 
necessarily 
(lentiviral 
vectors) 
No 
Yes (likely to 
be similar to 
pronuclear 
micro-
injection) 
Chimeric No 
Transgene 
capacity 
Unlimited: 
could even 
be used to 
deliver MACs 
9-10 kb 9-10 kb Not known 
Depends 
on 
transfection 
method 
Depends 
on 
transfection 
method 
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Expression 
Often low or 
aberrant, due 
to random 
integration 
Control 
possibilities 
limited by 
viral 
sequences 
Control 
possibilities 
limited by 
viral 
sequences 
Likely to be 
low or 
aberrant, due 
to random 
integration 
No 
problems in 
gene 
targeted 
outcomes 
No 
problems in 
gene 
targeted 
outcomes 
Scientific 
status 
Fully 
established in 
non-primate 
animals 
Well 
established 
in non-
primate 
animals 
Early 
success 
reported in 
primates 
Not well 
established 
despite 
several 
reports of 
success – 
theoretical 
difficulties  
Fully 
established 
– but only 
in mice 
Becoming 
well 
established 
Use in human 
germline GM 
conditional 
upon 
scientific 
break-
throughs? 
No No No No 
Yes: 
human 
ESCs 
required 
No  
Scientific 
advances 
required 
before method 
could become 
a practical 
proposition 
for human 
germline gene 
therapy  
Incremental 
improvement
s in efficiency 
ICM pre-
screening 
technology 
Use of 
‘insulator’ 
sequences in 
transgenes 
RVV 
design 
improved 
and tested 
to ensure 
safety 
Engineerin
g of RVV 
genome for 
improved 
transgene 
expression 
RVV 
design 
improved 
and tested 
to ensure 
safety 
Engineerin
g of RVV 
genome for 
improved 
transgene 
expression 
Establish-
ment of 
SMGT (must 
be reliable 
and 
repeatable) 
Development 
of augmented 
uptake 
methods 
n/a 
Improve-
ments in 
reprog-
ramming to 
avoid 
epigenetic 
problems 
Incrementa
l improve-
ments in 
efficiency 
Ideal improve-
ments 
Gene 
targeting via 
recombinase 
use 
Gene 
targeting 
by 
engineerin
g RVV 
genome 
Gene 
targeting 
by 
engineerin
g RVV 
genome 
Establishmen
t of AI-based 
SMGT as a 
reliable form 
of GM 
n/a n/a 
 
 
